Mechanism of baricitinib supports artificial intelligence‐predicted testing in COVID‐19 patients

Baricitinib is an oral Janus kinase (JAK)1/JAK2 inhibitor approved for the treatment of rheumatoid arthritis (RA) that was independently predicted, using artificial intelligence (AI) algorithms, to be useful for COVID‐19 infection via proposed anti‐cytokine effects and as an inhibitor of host cell v...

Descripción completa

Detalles Bibliográficos
Autores principales: Stebbing, Justin, Krishnan, Venkatesh, de Bono, Stephanie, Ottaviani, Silvia, Casalini, Giacomo, Richardson, Peter J, Monteil, Vanessa, Lauschke, Volker M, Mirazimi, Ali, Youhanna, Sonia, Tan, Yee‐Joo, Baldanti, Fausto, Sarasini, Antonella, Terres, Jorge A Ross, Nickoloff, Brian J, Higgs, Richard E, Rocha, Guilherme, Byers, Nicole L, Schlichting, Douglas E, Nirula, Ajay, Cardoso, Anabela, Corbellino, Mario
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7300657/
https://www.ncbi.nlm.nih.gov/pubmed/32473600
http://dx.doi.org/10.15252/emmm.202012697

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7300657/
https://www.ncbi.nlm.nih.gov/pubmed/32473600
http://dx.doi.org/10.15252/emmm.202012697

Ejemplares similares